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Introduction
Programmed regulation of transcription termination is one strategy for control of gene expression that is employed by a wide variety of organisms (Das, 1993) . This modulated readthrough of transcription-termination signals, called transcription antitermination, was originally postulated to explain the activation of coliphage l delayed-early genes by the phage-encoded N gene product (Roberts, 1969) . Genetic studies of this antitermination process have identified a set of Escherichia coli genes, nus, whose protein products are required for effective N-mediated antitermination (Friedman et al., 1984a) . Some of these Nus proteins serve as transcription-elongation factors for E. coli (reviewed by Yager and Von Hippel, 1987) and all are essential for host viability . The participation of a large number of proteins in antitermination raises the obvious question of how the members of such a collection of host and viral proteins interact with each other and, importantly, how the complex itself interacts with RNA polymerase (RNP) to create a termination-resistant transcription complex (Das, 1992; Friedman, 1988; Roberts, 1992; Greenblatt et al., 1993) .
Central to N-mediated modification of RNA polymerase are the nut signals (Rosenberg et al., 1978; Salstrom and Szybalski, 1978a) . Located downstream of the early 1982; Lazinski et al., 1989; Salstrom and Szybalski, 1978a,b; Barik et al., 1987; Olson et al., 1982; 1984; Warren and Das, 1984; Zuber et al., 1987; Nodwell and Greenblatt, 1991; Friedman et al., 1990; 1984a) to modify the transcribing RNA polymerase. The nut regions have been divided by sequence homologies, as well as by function, into two components Olson et al., 1984; Hasan and Szybalski, 1986; Lazinski et al., 1989) . The BOX-A component appears to be the recognition site for the NusB and possibly the S10 (NusE) proteins (Friedman et al., 1990; Nodwell and Greenblatt, 1993; Patterson et al., 1994) and an inhibitory host factor whose existence has been inferred from results of genetic and physiological studies (Patterson et al., 1994) . The BOX-B component, a region of hyphenated dyad symmetry that forms a hairpin, has been identified as the recognition site for N and NusA (Doelling and Franklin, 1989; Lazinski et al., 1989; Das, 1992; Chattopadhyay et al., 1995; Mogridge et al., 1995) . (Note that the following convention is being followed in labelling nucleic acid sites: the DNA site will be in lower-case italics and the RNA site will be capitalized, e.g. the DNA will be referred to as 'nut ', while the RNA will be referred to as 'NUT'.)
Most of the Nus factors were identified by mutations that influence the effectiveness of the N-mediated antitermination process without affecting host viability. Subsequent in vitro studies confirmed the essential roles of these products in this antitermination process (Das and Wolska, 1984; Horwitz et al., 1987) . Two types of mutations were employed in those studies. The first are mutations that cause a failure in N-mediated antitermination at higher temperatures, a phenotype we shall refer to as Nus 7 (N undersupplied). Two of these mutations, nusA1 at minute 69 and nusB5 at minute 11 on the E. coli chromosome, are located in genes that had not previously been identified and thus were defined by their antitermination defect. Three are in genes that were of known function: rpsJ/nusE, encodes ribosomal protein S10 and is located at minute 72; rho/nusD, encodes the Rho transcription-termination protein and is located at minute 90; and rpoB, encodes the b subunit of RNA polymerase and is located at minute 85 (reviewed in : Friedman et al., 1984a; Das, 1992; Greenblatt et al., 1993; Friedman, 1992) . Hosts with any of these nus mutations have a reduced ability to support l growth, solely because of a defect in N-mediated antitermination.
The other type of mutations used to identify host factors involved in N action are second-site suppressors that were isolated on the basis of restoring N antitermination activity in the presence of nusA1. Second-site suppressor mutations of this type were identified as rif r mutations in the rpoB gene (Sparkowski and Das, 1992; Jin et al., 1988) , the nusB101 mutation (Ward et al., 1983; Court et al., 1995) and the nusG4 mutation in a previously unidentified gene (Downing et al., 1990) . In vitro studies provided evidence that NusG is a component of the N-antitermination complex (Li et al., 1992) . However, its role in antitermination has not been definitively established, because depleting NusG in the cell does not result in reduced antitermination . Although other phenotypes associated with mutations in nus genes have been identified (Tsugawa et al., 1988; Ward et al., 1983; Kur et al., 1989; Kuroki et al., 1982; Ward and Gottesman, 1981; Zheng and Friedman, 1994; Court et al., 1995) , this discussion will be limited to those mutations that influence N action by causing or suppressing a Nus 7 phenotype. The nusB101 and nusG4 mutations also suppress the Nus 7 phenotype imposed by the nusE71 mutation (Ward et al., 1983; . Mutations identified in l that exhibit similar suppression of the nusA1 and nusE71 mutations have been located in the nutR-boxA sequence (Friedman et al., 1990) and in the N gene (Schauer et al., 1987; Franklin, 1985) . These mutations were initially selected because they fostered l growth in E. coli nusA1 mutants, but they subsequently were also shown to foster l growth in E. coli nusE71 mutants (Schauer et al., 1987; . With the exception of nusB101, which was not tested for the obvious reason that it is a nusB mutation, all of these suppressors, bacterial as well as phage, show relatively poor suppression of the Nus 7 phenotype conferred by the nusB5 mutation (Schauer et al., 1987; Ward et al., 1983) . It has been suggested that suppressor mutations that alter a component of the N-Nus complex suppress because they enhance (one or more) interactions in the complex, compensating for a suboptimal interaction caused by the primary nus mutation (Schauer and Friedman, 1985; Das, 1992) .
We report that mutations in the rpoA gene also suppress defective N-Nus-mediated transcription antitermination caused by nus mutations. These rpoA mutations change amino acids within a small segment of the carboxy terminal domain (CTD) of the a subunit of RNA polymerase, indicating that a distinct molecular surface may contribute to the control of the activity of the N-Nus complex.
Results
Selection of rpoAD305E, a second-site suppressor of nusE71
The rpoAD305E mutation, originally called sneA16 (Friedman, 1988; Schauer, 1985; Schauer and Friedman, 1985) , was isolated by selecting for second-site mutations that suppress the Nus 7 phenotype of an E. coli strain carrying the nusE71 mutation. The selection was essentially that devised by Ward et al. (1983) . The E. coli strain (K1953) used in the selection carries the nusE71 mutation and has the gal operon under the control of the l pL promoter (Fig. 2) . Because of intervening transcription terminators, expression of gal genes is entirely dependent on Nmediated transcription antitermination. Even though N is expressed, the strain is Gal
7
, because the nusE71 mutation does not support N action. Thus, suppression of this nusE71 defect would result in a Gal + phenotype. We attempted to direct the mutagenesis to the 72 min region using P1 transduction for localized mutagenesis (see the Experimental procedures). This region of the E. coli chromosome was chosen as a possible location of suppressor mutations, because it is rich in genes encoding ribosomal proteins. We postulated that if one or more ribosomal proteins interacted with S10 during antitermination, a mutation in one of the genes encoding such a protein might suppress the effect of the nusE71 mutation. The marker selected in the transduction was a Tn10 transposon, zhb-3082::Tn10, located in this region. The rpoAD305E mutation, obtained from this selection, was located on the E. coli genetic map using standard genetic techniques (Miller, 1972; Sternberg and Maurer, 1991) . These manipulations located the rpoAD305E mutation, as expected, in the 72 min region of the E. coli chromosome, and finer mapping studies suggested that the mutation is in or closely linked to the rpoA gene, which encodes the a subunit of RNA polymerase.
Complementation analysis and marker rescue
The dominance of the rpoAD305E mutation was characterized using a strain with the rpoAD305E allele on the chromosome. The effectiveness of N action could be assessed because the bacterium carries the pL-gal fusion described above and also in Fig. 2 . The bacterium, E. coli K6325, carries, in addition to the fusion, the nusE71 mutation that normally blocks N action, but because K6325 also carries the rpoAD305E mutation, this blockage of N action is suppressed. The gal operon can be expressed allowing K6325 to metabolize galactose and thus to form red colonies on a MacConkey-galactose plate at 408C. A derivative of K6325 containing pNO2530 (a plasmid with the wild-type rpoA and rplQ genes downstream of plac) (Bedwell and Nomura, 1986) forms pink colonies, reflecting a reduction in gal operon expression and thus a reduced suppressor phenotype. Note that under these conditions K1953, the starting nusE71 derivative, forms white colonies (low gal-operon expression) and K1947, the nus + derivative, forms red colonies (high galoperon expression). Thus, by this assay, rpoA + expressed from the pNO2530 plasmid is only partially dominant to the single chromosomal copy of the rpoAD305E allele. A plasmid with the rpoAD305E allele was obtained from K6325 carrying pNO2530 by identifying rare red colonies on MacConkey-galactose plates containing ampicillin, at 408C. Presumably these red-colony formers became homozygous for rpoAD305E as a result of recombination between the chromosomal and plasmid rpoA alleles and subsequent segregation. The details of the screen for the recombinants and the tests confirming the exchange are described in the Experimental procedures. When this new rpoAD305E-containing plasmid, isolated from these red colonies and named pNO2530*, is transformed into the rpoA + strain K1953, the nusE71 defect is suppressed (there is effective gal operon expression as evidenced by formation of red colonies), indicating the trans-dominant nature of the suppressor rpoAD305E mutation in multicopy.
Locating the rpoAD305E mutation to the rpoA gene
The rpoA insert in pNO2530 is located immediately downstream of the lac promoter (plac). To determine whether rpoAD305E was an allele of rpoA, we subcloned DNA fragments from pNO2530 and pNO2530* and placed Fusion for selecting the rpoAD305E mutation and for assessing levels of suppression of nus mutations (after Ward et al. (1983) ). The bacterium is a derivative of E. coli K-12 in which the bacterial galactose operon (gal ) is fused to the pL promoter of a defective l prophage. The essential components of this abbreviated prophage are: a c I mutation eliminating repressor, the pL promoter, the nutL signal, the N gene, and transcription terminators, including a strong termination signal in an IS2 positioned immediately 5' of the structural genes of the gal operon. In a nus ). Bacteria with second-site mutations that suppress the nusE71 mutation were selected as Gal + mutants.
them in the appropriate orientation for expression, downstream of the tac promoter (ptac) in a derivative of plasmid pKK223-3 (de Boer, 1984) , as shown diagrammatically in Fig. 3 . The resulting plasmids were tested for suppression of the nusE71 mutation. Plasmid pKKrpoA*, which includes the complete rpoA gene and the 5' two-thirds of rplQ from pNO2530*, suppresses the nusE71 mutation, whereas the same region from pNO2530 did not. Another plasmid, which includes only the 3' end of rpoA as well as the 5' two-thirds of rplQ from pNO2530* (our unpublished results), fails to suppress the nusE71 mutation. Thus, we conclude that rpoAD305E is indeed an allele of rpoA.
Sequencing the rpoAD305E mutation
Comparison of the DNA sequences of the rpoA genes in pNO2530 and pNO2530* revealed a single nucleotide difference. The former has GAC at codon position 305 as does the published sequence (Meek and Hayward, 1994) , while the latter has GAA at that codon position. The derived amino acid sequence for the mutant a subunit has a glutamic acid at position 305 instead of aspartic acid encoded in the wild-type a subunit at that position; we have sequenced the entire fragment that expresses suppressor activity and find this to be the only change from the wildtype sequence. Additionally, sequencing of the mutant chromosomal allele reveals the same change. Therefore, we conclude that the change from an aspartic to a glutamic acid at amino acid position 305 is responsible for the rpoAD305E Nus-suppressor phenotype.
Suppression of other nus mutations
To characterize the range of suppression by the rpoAD305E mutation, we assessed the effect of rpoAD305E on the Nus 7 phenotypes imposed by mutations in other nus genes. Derivatives of strain K37, each carrying the rpoAD305E mutation in addition to one of the nus mutations, were tested for their ability to support l growth at high temperatures using efficiency of plating (EOP) as the assay for l growth (Table 1) . Results of this assay show that the rpoAD305E mutation suppresses the Nus 7 phenotypes imposed by all three nus mutations. In this and other assays testing Nus activity, different temperatures were used in assessing the Nus 7 phenotype: 408C for those with nusB5 or nusE71 mutations, and 428C for those with the nusA1 mutation (Friedman et al., 1984a (Brosius and Holy, 1984) with cloned rpoA genes. The circles show the cloning vector, and the diagrams above show the nature of the cloned fragment in each construct. rrnB T1T2 are terminators from the rrnB operon. The position of the amp r gene is indicated. The cloned rpoA genes are oriented so that they are expressed from the ptac promoter. On the left is shown the extent of the fragment cloned in both pKKrpoA and pKKrpoA*, and on the right is shown the extent of the fragment cloned in pKKrpoAD3'. The region of pKK223-3 between the SphI and PvuII sites was deleted in all of these plasmids. one of these nus-mutant strains results in an increase of the EOP to nearly 1. We next employed a more direct assay to assess the degree of suppression by the rpoAD305E mutation. Suppression was quantitatively assessed using bacterial derivatives with the previously described pL-gal fusion (Fig. 2) . As shown in Table 2 , hosts carrying any one of the three nus mutations (nusA1, nusB5, or nusE71) express galK levels that are~10% of that observed in the K1947 nus + control. In the double rpoAD305E nus mutants, galK expression was significantly higher, varying from 30-100% of that observed in the nus + control.
Although there were differences in the level of suppression, the essential point is that the results of this test, similiar to those from the phage plating, show that rpoAD305E suppresses the Nus 7 phenotype of the three nus mutations.
Suppression by a truncated rpoA gene
In vitro studies on the action of transcription activators have shown that RNA polymerase with an a subunit deleted at the carboxy terminus duplicates the effects of point mutations that change specific amino acids in the carboxy terminus of a (Ishihama, 1992) . To determine if there was a similar effect on suppression of nus mutations, we examined whether the truncated a subunit, expressed from an rpoA gene deleted for its 3' domain, affects the Nus 7 phenotype of E. coli derivatives with nus mutations. E. coli strains haploid for an rpoA 3' deletion are not viable, but plasmids expressing the truncated rpoA can be maintained in strains that are wild type for rpoA (Hayward et al., 1991) . Based on these findings and our observation that plasmids expressing the rpoAD305E allele are trans-dominant, we postulated that a 3' deletion of rpoA might suppress the Nus phenotype. This hypothesis was tested using a plasmid expressing the 3'-deleted rpoA gene. Three plasmids, pKKrpoA, pKKrpoA*, and pKKrpoAD3' (see Fig. 3 ), were tested in parallel for suppression of nus mutations.
Sequence analysis predicts that pKKrpoAD3' should express an a subunit that is truncated at amino acid 229 where an additional 15 amino acids encoded by the vector sequence are added. Western blot analysis, using an anti-a monoclonal antibody, identified a protein corresponding to the size predicted for the truncated polypeptide in bacteria carrying pKKrpoAD3'. This protein is not seen in control bacteria that do not contain the plasmid (data not shown).
The suppressor activity of the plasmid-based rpoA alleles was examined by assessing the effects on l growth as measured by EOP. As shown in Table 3 allele is lower in the nusA1 mutant than in the nusE71 mutant could suggest a difference in suppression, but also could result from complications owing to the presence of the wild-type rpoA allele. The pattern of suppression of the nusB5 mutation is qualitatively different. By this test the rpoAD3 ' mutation, similar to the wild-type allele, fails to suppress the nusB5 mutation, while the rpoAD305E allele does so weakly. We emphasize the essential finding from these experiments that the rpoAD3 ' allele, like the rpoAD305E allele, suppresses the Nus 7 phenotype of some nus mutations, while pointing out the difficulty in assessing the significance of the quantitative data because of the possibility of interference with suppression by the wild-type rpoA allele. a. See Fig. 2 for details on the pL-gal construct. b. Percent readthrough equals (GalK level expressed from the fusion in the mutant strain divided by the GalK expressed from the fusion in the parent strain (wild type for relevant markers))6100. GalK levels were measured as indicated in the Experimental procedures. 
Effect on transcription initiation and termination
Studies presented in the previous sections show that rpoA mutations can suppress the effect of mutations in three E. coli genes whose products influence N-mediated transcription antitermination. There are two ways to explain this suppression by an rpoA mutation, either by an increase in transcription initiation or by a decrease in transcription termination. Therefore, we assessed the effect of the rpoAD305E mutation on transcription initiation and termination in the absence of N. Beta-galactosidase levels were compared between congenic rpoA + and rpoAD305E
strains carrying a pL-N-lacZ protein fusion in a defective prophage. There was essentially no difference between the two strains with regard to promoter strength or N expression, because each expressed~2000 units of the b -galactosidase fused to N. Termination was assessed using three pKL600 derivatives that test the tR2 Rhoindependent or tR1 and tR3 Rho-dependent terminators of phage l (Cheng et al., 1991; Patterson et al., 1994) . Because the transcription terminators are placed upstream of the galK gene, expression of galK provides a measure of termination. We found that the rpoAD305E mutation did not have any significant effect on these terminators (data not shown).
Effect of other rpoA alleles
We employed a l variant carrying the cro62 mutation to screen other mutations in the carboxy terminus of rpoA for this suppressor phenotype. The cro62 mutation results from a deletion of a single base pair (bp) in the 3' terminus of the l cro gene (Olson et al., 1982) that causes a shift in the cro reading frame, resulting in translation extending four nucleotides downstream of the usual UAA termination codon to a UAA codon in the new reading frame. This extension of translation moves the terminating ribosomes closer to the 5' junction of NUT-R (three nucleotides away instead of seven nucleotides away) and causes a failure in N-mediated antitermination (Olson et al., 1982) . Presumably, the shift downstream of the terminating ribosomes interferes with the assembly of the antitermination complex at NUT-R (Olson et al., 1984) . This defect in antitermination results in the failure of l cro62 to grow in K37 which is wild type for nus alleles; however, l cro62 grows in K4069, which is a K37 derivative carrying the rpoAD305E mutation. l cro62 exhibits a four-log-greater EOP on a lawn formed from K4069 than from a lawn formed from K37 and also shows a similar high EOP on a lawn formed from a K37 derivative carrying a plasmid with the rpoAD3' allele.
We exploited our observation that the rpoAD305E mutation converts E. coli from being non-permissive to being permissive for l cro62 growth, to screen other rpoA mutations for this suppressor phenotype. A number of rpoA mutations constructed in E. coli C (Ayers et al., 1994) were tested for their ability to enhance antitermination by examining l cro62 growth (Table 4) . Two control experiments confirmed that we could use this set of otherwise isogenic mutants for this screen. First, l cro62 fails to form plaques on a lawn formed from the parental E. coli C strain containing the wild-type rpoA and, second, l cro62 forms plaques on a derivative of this E. coli C that carries the rpoAD305E mutation. Table 4 lists the seven rpoA E. coli C derivatives tested, and specifies the amino acid change in the encoded a subunit of each strain. This test identified only one other strain, C4540, which had an rpoA mutation that suppresses the antitermination defect. The rpoA mutation in this strain results in a Leu to His change at amino acid position 290.
Discussion
The a subunit of E. coli RNA polymerase has been identified as the probable site for interaction of a number of transcription factors (Ishihama, 1992; Russo and Silhavy, 1992; Ebright and Busby, 1995; Giladi et al., 1992) . Mutations influencing the action of such transcription factors are usually found in non-overlapping clusters in the 3' region of the rpoA gene. Proteolytic treatment of the 329-amino-acid a subunit revealed that the carboxy terminal 85 amino acids form a domain (CTD) that dimerizes and binds to DNA (Blatter et al., 1994) . The CTD includes the amino acids changed by the mutations that interfere with the action of transcription activators. Clusters of mutations are located at the following amino acid positions: (i) 265-270, influencing the action of the cAMP-binding protein at the lac P1 promoter (Zou et al., 1992) ; (ii) 289-290, influencing the Ogr protein of phage P2 (Ayers et al., 1994; Sunshine and Sauer, 1975) ; (iii) 311-317, influencing the action of Fnr (an activator of anaerobically expressed genes) (Lombardo et al., 1991) ; and (iv) 322 or 323, influencing the action of OmpR and EnvZ (which are regulators of porin expression) (Slauch et al., 1991) .
We have identified an rpoA mutation, rpoAD305E, that changes amino acid 305 in the CTD of a . This altered a subunit suppresses a variety of mutations, including those in nus genes, that reduce the effectiveness of the N-mediated transcription antitermination system of phage l . A screen of seven other rpoA mutations that alter the a CTD and affect transcription-initiation factors (Ayers et al., 1994) identified one additional mutation that exhibits suppression of a defect in N-mediated antitermination. This mutation, rpoA109, changes amino acid 290 of the a subunit and was originally identified because it interferes with the action of the phage-encoded Ogr transcription-activation protein (Sunshine and Sauer, 1975) . Those changes in the CTD of a that had no effect on N-mediated antitermination altered amino acids are at positions 215, 271, 272, 322, and 323. These mutations are all thought to affect transcription initiation, while the rpoAD305E mutation influences transcription elongation. Moreover, selections that yielded rpoA mutations that affect the actions of other transcription factors have not yielded, to our knowledge, any mutations in codon 305. Thus, amino acid position 305 appears to have specificity, in this case, for an interaction influencing transcription elongation. Preliminary studies suggest that rpoAD305E, unlike rpoA109 (L290H ), does not affect P2 Ogr function (G. Christie, personal communication). Thus, there appears to be overlap, but not identity, of amino acid patches used by the Ogr initiation activator of P2 and the N antitermination system of l . RNA polymerase reconstituted with an a subunit truncated in its CTD also fails to interact with, and is not stimulated by, activator proteins (Ishihama, 1992) . This led to the idea that the point mutations cause changes in the a subunit that block interaction with the activators. To determine if something similar is occurring with rpoAD305E, we examined the effect of a 3'-truncated rpoA gene on Nmediated antitermination and found that the truncated gene product, like the product of the rpoAD305E allele, suppresses the defect in antitermination caused by nus mutations. These observations raise questions regarding the nature of the interaction influenced by rpoAD305E. If the results of only the experiments with rpoAD305E were to be considered, a simple explanation for our observations would be that the rpoAD305E mutation enhances the interaction of one, or more, of the components of the N-Nus complex with RNA polymerase. Accordingly, this enhanced interaction could compensate for an impaired interaction of another component. The observation that a variant a subunit missing its carboxy terminus also suppresses some Nus 7 phenotypes calls into question enhanced interactions of the a CTD as the cause for suppression by the rpoAD305E mutation. Because the truncated a subunit is missing amino acids that include amino acid 305, suppression cannot be mediated by facilitation of an interaction with amino acids at and near 305 in the carboxy terminus, but, instead, it probably results from a failure to interact with amino acids in this region. This means that rpoAD305E is not sui generis, but, like the other rpoA mutations, is affecting regulatory activity by blocking an interaction with the a subunit. We suggest that antitermination is restored for one of two reasons: either rpoAD305E and rpoAD3 ' reduce transcription termination or they enhance antitermination. Our experiments with tester systems designed to measure terminator activity appear to rule out the first explanation, because the rpoAD305E mutation has no effect on several l transcription terminators in the absence of N.
We therefore favour the latter explanation, namely that the rpoA mutations stimulate antitermination. This stimulation is unlikely to be caused by overexpression of N or any of the Nus factors. First, overexpression of N, NusA, NusE, or NusG fails to duplicate the suppressive effects observed with the rpoAD305E mutation (our unpublished results). Second, the rpoAD305E mutation partially suppresses a nusB null mutation for l growth (M. Neeley, D. Court, and D. Friedman, unpublished) , showing that NusB is not necessary for the suppression activity of rpoAD305E.
Models explaining how mutations in the a subunit enhance impaired N-mediated transcription elongation would necessarily depend on interactions of a that might occur either at initiation or during elongation of transcription. The former would involve DNA and/or proteins at the promoter in a manner similar to interactions previously described for transcription activators, while the latter would involve interactions downstream of the promoter with the RNA, DNA, and/or a protein(s) composing the antitermination complex. Regardless of the site of the interaction, under conditions of impaired N action, the final signal to RNA polymerase must result in a failure in N-mediated antitermination that can be relieved by mutations in rpoA. Although we have shown that transcription levels from the l pL promoter are not affected by the rpoAD305E mutation, this does not rule out the possibility that a activity at the pL promoter affects transcription antitermination, but in an indirect manner.
As opposed to action at the promoter with a subsequent effect on elongation, a could affect the elongation process per se. For example, an interaction between a and the DNA, similar to that observed at the rrn promoter (Ross et al., 1993) but in this case during elongation, might render polymerase less susceptible to modification by N and Nus factors. Alternatively, an interaction between a and the NUT RNA might hinder formation of the antitermination complex directly, either by interfering with complex formation or by facilitating action of an inhibitor of Nmediated antitermination-complex formation. Liu and Hannah (1995) have shown that, in vitro, the a CTD interacts with the nascent RNA during transcription and this interaction is not observed in the presence of NusA. We have proposed an inhibitor to explain the results of our genetic and physiological studies (Patterson et al., 1994) , and an inhibitor was also suggested to explain NusB-independence for processive N-mediated antitermination in vitro with purified protein components (DeVito and Das, 1994) . The inhibitor could conceivably prevent antitermination, in part, by interacting with the a subunit of RNA polymerase. According to this model, the suppression observed with rpoAD305E and rpoAD3 ' mutations (and presumably rpoAL290H ) results from a reduction in the interaction between a and the inhibitor. This loss of inhibitor action, in turn, would permit a more unencumbered assembly of the N antitermination complex. Under conditions where all components are functioning effectively, the action of the inhibitor would be effectively blocked. However, under conditions less optimal for formation of antitermination complexes (e.g., in the presence of nus mutations), the presence of the inhibitor would interfere with complex formation, leading to a failure in antitermination. Thus, loss of the inhibitor activity would allow for effective complex formation under the suboptimal conditions and result in effective antitermination.
We are unable to propose a definitive model to explain how the rpoAD305E and rpoAD3 ' mutations suppress the inhibitory effect on l growth caused by the cro62 frameshift mutation, i.e., why l cro62 fails to grow in a nus + host, K37, but grows in a derivative of K37 that carries copies of either the rpoAD305E or rpoAD3
' alleles. However, we offer the following hypothesis to explain this observation. The cro62 frameshift results in an incursion of translating ribosomes into the NUT region (Olson et al., 1984) that appears to compete with the efficient entry of N and/or Nus factors to the NUT site. We suspect that the enhancement of N action mediated by the a mutations tilts this competition in favour of N and thus allows growth of l cro62. In vitro studies by Liu et al. (1996) found that RNA polymerase containing a subunits missing the carboxy terminal domain can be modified by N and Nus factors into effective antitermination complexes. This indicates that the carboxy terminus of a is not required to assemble the antitermination complex and is consistent with the arguments we have advanced regarding the requirement for the carboxy terminal domain of the a subunit and the putative inhibitory factor.
A role for an inhibitor of transcription elongation has been described in humans. A 213-amino-acid protein encoded by the VHL tumour-suppressor gene has been proposed to modulate transcription by inhibiting action of the SIII transcription-elongation factor (Latif et al., 1993; Duan et al., 1995) . Interestingly, it has been pointed out that portions of the p15 subunit of SIII share sequence similarity with the E. coli NusB and Rho transcriptionelongation proteins (Garrett et al., 1994) .
In summary, we have presented evidence showing that an interaction that promotes transcription elongation appears to be regulated through interactions with the a subunit of RNA polymerase. As many other studies have identified a role for the a subunit in initiation of transcription, our studies identify an expanded role for this subunit in the transcription-elongation process.
Experimental procedures

Bacteria
Relevant genotypes and sources of bacteria used in these studies are listed in Table 5 .
Media
The media used in these experiments have been described previously (Miller and Friedman, 1980) . Plasmids pNO2530, pNO2341, pNO2685, and pNO2695 were supplied by M. Nomura (Cerretti et al., 1983) . pNO2530* was obtained by recombining the rpoAD305E mutation from the chromosome with pNO2530. pKKrpoA (Fig. 3) was constructed by isolating a 1318 bp Hin dIII-NruI fragment, which contained all of rpoA and a 5' portion of the adjacent rplQ gene from pNO2530, and ligating it into the Hin dIII site of pKK223-3 (Brosius and Holy, 1984) . The resulting plasmid was deleted of 1503 nucleotides of pKK223-3 located between the SphI and PvuII sites. The identical procedure was followed to construct pKKrpoA*, except that pNO2530* was used as the donor of the Hin dIII-NruI fragment. pKKrpoAD3' was constructed by cloning the 711 bp Hin dIII fragment from pNO2530, containing a truncated rpoA gene deleted of its 3'-terminal 300 nucleotides, into the Hin dIII site of pKK223-3 (also deleted for the 1503 nucleotides between the SphI and PvuII sites). pKL600, supplied by K. McKenney, is a terminator-tester plasmid that has a polycloning site between plac and a galK reporter gene (McKenney et al., 1981) . pKLtR2 and pKLtR3 are derivatives of pKL600 that have the tR2 (Rho-independent) or tR3 (Rho-dependent) terminators, respectively, of l cloned in the proper orientation in the polycloning site (Cheng et al., 1991; .
Phage and source l cI60 and l cI857 were obtained from the NIH collection; l cI857cro62 is from these laboratories.
#
Phage techniques
Efficiency of phage plating (EOP) was determined as described previously (Friedman et al., 1984b) . Dilution spot tests used to obtain a semi-quantitative evaluation of phage growth were performed by spotting drops of serial dilutions of phage on lawns formed from the indicated bacterium and scoring growth according to the dilutions that showed phage growth.
Nucleic acid and protein procedures DNA preparation, restriction enzyme digestions, ligations, and transformations were performed essentially as described by Sambrook et al. (1989) . Protein purification and twodimensional electrophoresis of ribosomal proteins have previously been described (Friedman et al., 1981) . Western analysis was performed as previously described (Craven et al., 1994 (Yanisch-Perron et al., 1985) carrying the desired cloned fragments served as single-stranded DNA templates for sequencing. The sequencing reactions were run on a six or eight percent polyacrylamide gel for varying lengths of time. Both strands of the DNA were sequenced.
Galactokinase assay
Enzyme levels were measured according to the published method (Adhya and Miller, 1979) .
Beta-galactosidase assay
Enzyme levels were measured according to Miller (1992) .
Genetic techniques P1 transduction and Hfr crosses were performed in the standard manner (Miller, 1972; Sternberg and Maurer, 1991) .
Selection for second-site suppressors of nusE71
This scheme, devised by Ward et al. (1983) , uses derivatives of an E. coli K-12 strain, K1947, that has a fusion of the bacterial gal operon to the pL promoter of a defective l prophage. The abbreviated prophage also has the associated nutL signal, N gene, and a defective c I allele (Fig. 2) . Additionally, there are at least two transcription-termination signals located between pL-nut and the gal operon. One of the terminators is located in an IS2 positioned in the leader region of the gal operon. This Rho-dependent terminator is very efficient and, therefore, in this construct, transcription initiating at pgal should terminate upstream of the gal genes. However, the prophage in K1947 does not express an active repressor and constitutively expresses N from the pL promoter. The expressed N, in turn, modifies the RNA polymerase transcribing the pL operon, allowing transcription to transcend all downstream terminators and read into the gal operon, producing a Gal + phenotype. In our adaptation of the selection, a derivative of K1947, K1953, carries the nusE71 mutation, causing N to be ineffective. Hence, the bacterium is Gal 7 even though N expression is constitutive. Suppressors of the Nus 7 phenotype should result in the bacteria being Gal + because N action would be supported. Gal + colonies were obtained (at a frequency of 10 7 8 ) and~80% of these supported l growth and, therefore, supported N action more effectively than did the starting parental recipient. We attempted to limit the mutant search to the 72 min region of the E. coli chromosome which has a large number of genes encoding ribosomal proteins (Nomura et al., 1977) . Localized mutagenesis (Hong and Ames, 1971) was employed using hydroxylamine treatment of a P1 lysate grown on a nusE71 host, K2016. This bacterium has a Tn10 insertion (Kleckner et al., 1991 ) (zhb-3082::Tn10, conferring resistance to tetracycline (Tet R )) linked to the 72 min region (Singer et al., 1989) . Because P1 transducing particles can package 100 kb (2%) of the E. coli chromosome (Sternberg and Maurer, 1991) , it was expected that by using this lysate to transduce for Tet R , we would enrich for mutations in the 72 min region. Second-site suppressors were distinguished from true revertants using two-dimensional gel electrophoresis to determine if the S10 protein maintained the altered mobility caused by the nusE71 mutation (Friedman et al., 1981) . One mutant, K2090, identified as having a second-site suppressor, was chosen for further characterization. The second-site mutation, rpoAD305E, was located to the 72 min region of the E. coli genetic map by cotransduction with zhb-3082::Tn10. As the predominant change caused by hydroxylamine mutagenesis is C to T (Budowsky, 1976) , we assume that the rpoAD305E mutation did not result from the hydroxylamine treatment but, instead, from a spontaneous mutation. The selection of an apparent spontaneous mutation following in vitro hydroxylamine mutagenesis of phage is not without precedent (Min Jou et al., 1972) .
Marker rescue of rpoAD305E K6325 (a derivative of K2090 with a substitution of a kan r marker for the tet r marker of zhb-3082::Tn10) carrying pNO2530 was employed to transfer the rpoAD305E mutation to the plasmid by recombination between the chromosome and the cloned genes of the plasmid. Colonies containing such candidate recombinant plasmids were identified on MacConkey-galactose plates that contained ampicillin (30 m g ml 7
1
) to maintain selective pressure for the plasmids. The starting strain has the rpoA + allele on the plasmid and the rpoAD305E mutation on the chromosome. Because of partial dominance of rpoAD305E, K6325 with pNO2530 forms pink colonies on these indicator plates, unlike K6325, which forms dark-red colonies. However, dark-red colonies were occasionally observed (~1/100) when K6325 harbouring pNO2530 was plated on MacConkey-galactose-ampicillin plates. When these colonies were restreaked on the indicator plates containing ampicillin, dark-red colonies could be isolated. These bacteria obviously expressed higher levels of gal enzymes than those forming the pink colonies. We assumed that the rpoAD305E allele had recombined from the chromosome to the plasmid and the bacteria had become homogenotized for the mutant allele.
Plasmid DNA was isolated from a dark-red colony and this plasmid, named pNO2530*, was shown to have an insert that was seemingly identical to pNO2530. However, unlike pNO2530, pNO2530* suppressed the Nus 7 phenotype; when pNO2530* was transformed into the nusE71 parent strain, K1953, dark-red colonies were formed on MacConkey-galactose plates. The suppressor activity of pNO2530* was also assessed by phage plating. At 408C, l will not form plaques on a lawn of K1953, because N-mediated antitermination is inoperative. l also fails to form plaques on a lawn of a derivative of K1953 carrying pNO2530, but does form plaques on a lawn of a derivative of K1953 carrying pNO2530* (data not shown). These results lead us to conclude that the rpoAD305E mutation had recombined from the chromosome to the plasmid, and that pNO2530* carries the rpoAD305E mutation.
Crossing rpoAD305E away from nusE71
A triple nusA1 nusE71 rpoAD305E mutant is thermosensitive, growing only at temperatures below 428C. Previous studies had shown that a nusA1 nusE71 double mutant grows at 428C but fails to support growth of N-dependent l phage . Thus, if the rpoAD305E mutation suppresses the Nus 7 phenotype imposed by the nusA1 mutation, we suspected that it would be possible to select and screen for a nusA1 rpoAD305E double mutant following P1 transduction from the nusE71 rpoAD305E zhb-3082::Tn10 donor to a nusA1 recipient. This could be accomplished by selecting for Tet R colonies at 428C and screening the survivors for their Nus phenotype. Because nusE71, rpoAD305E, and zhb-3082::Tn10 are linked, one expected class of recombinants, triple nusA1 nusE71 rpoAD305E mutants, should be selected against by growing at the high temperature. Surviving bacteria that do not have rpoAD305E, but carry nusA1 only, or nusA1 and nusE71, should not support l growth at 428C. We expected that the nusA1 rpoAD305E double mutant might grow and support l growth at 428C. Recombinant progeny of such a cross were obtained at 428C and screened for support of l growth at 428C; 4% of the Tet R bacteria had this phenotype. One such recombinant, K4047, was chosen for further study. Genetic outcrosses confirmed that this recombinant contains the nusA1 and rpoAD305E mutations (data not shown).
A nus + recombinant, K4069, that has the rpoAD305E mutation free of any nus mutations was constructed by P1 transduction using K4047, the nusA1 rpoAD305E strain, as the donor. The recipient was the K37 nus + strain and the selective marker was the zhb-3082::Tn10 located near rpoAD305E. We could not ascribe any phenotype to the rpoAD305E mutation per se; therefore, potential rpoAD305E and zhb-3082::Tn10 recombinants were backcrossed to the nusA1 mutant, K95. Because the Tn10 is near rpoA, we assumed that if a donor harboured the rpoAD305E mutation then some of the Tet R recombinants generated in the backcross would also acquire the rpoAD305E mutation. When one Tet R K37 derivative, K4069, was the donor in the backcross to K95, 14/30 Tet R transductants scored as having suppressors of the Nus 7 phenotype, demonstrating that the donor K4069 strain contains the rpoAD305E allele. the University of Michigan was supported by Public Health Grant AI11459-10 and GCRG Grant M01-RR0042 for sequence analysis. This research was also sponsored, in part, by the National Cancer Institute, DHHS, under contract with ABL. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
